open-label PTH(1-84)

Phase 3Small molecule

CColumbia University

open-label PTH(1-84) is one of 20 small molecule programs targeting Hypoparathyroidism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoparathyroidismActive, not recruiting

HypoparathyroidismPhase 3

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Hypoparathyroidism

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Approved

3 2

Rocaltrol

Alnylam Pharmaceuticals

Approved

—3

Calciferol

Alnylam Pharmaceuticals

Klor-Con

1 5

One-Alpha

Roche

Phase 2

1 6

Forteo

AAlmaject

Phase 2

2 7

Calcium Citrate

CCampus Bio-Medico University

Approved

1 8

Tums

Otsuka

Phase 2

1 9

Rhpth

Takeda

Phase 3

5 10

Transcon Hgh

VVisen Pharmaceuticals (Shanghai) Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypoparathyroidism1 trial

HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism

Completed·—·Phase 3·NCT01199614·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for open-label PTH(1-84). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — open-label PTH(1-84) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for open-label PTH(1-84). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Columbia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CColumbia University

open-label PTH(1-84)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypoparathyroidism1 trial

References

Drug Info

Quick Facts

Related News